What is the Mankind Pharma Ltd share price today?

The share price of NSE:MANKIND-EQ on 01 Oct 2026 (as of 15:04:12 IST) is ₹2520.1.

What is the NSE:MANKIND-EQ 52 week high low price?

Over the past 52 weeks (as of 01 Oct 2026), the NSE:MANKIND-EQ 52 week high low range shows a high of ₹2642 and a low of ₹1909.7.

What is the Mankind Pharma Ltd market cap?

As on 01 Oct 2026, Mankind Pharma Ltd market cap is ₹1034680000000.

What is the shareholding pattern of Mankind Pharma Ltd Stock?

The shareholding pattern of Mankind Pharma Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 72.63% Foreign Institutional Investors (FII): 9.45% Domestic Institutional Investors (DII): 4.48% Mutual Funds: 10.87% Retail & Others: 2.57% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Mankind Pharma Ltd?

The Price-to-Earnings (PE) ratio of Mankind Pharma Ltd is 50.6532, and the Price-to-Book (PB) ratio is 5.0947, as on 01 Oct 2026.

Mankind Pharma Share Price

2400.00+31.50 (+1.33%)

-2.44% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

+1.33%

1 Week

-4.00%

1 Month

+5.26%

3 Month

-5.18%

6 Month

+13.08%

YTD

+9.26%

1 Year

-2.44%

5 Year

10 Year

Max

+84.62%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

2368.50

2342.00

2242.10

2222.00

2094.00

1909.70

High

2426.80

2510.90

2559.00

2642.00

About

Mankind Pharma is India’s one of the leading pharmaceutical company with a diversified portfolio - from pharma and super specialty to consumer healthcare backed by strong in-house R&D capabilities with Read more

Pharmaceuticals & Drugs

Midcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

ZYDUSLIFENSE

LAURUSLABSNSE

CIPLANSE

DRREDDYNSE

MANKINDNSE

AUROPHARMANSE

LUPINNSE

LTP

1W Low

1W High

Market cap (₹)

1760-21 (-1.18%)

1745

1796

4,21,539Cr

9426-162 (-1.69%)

9273

9658

2,47,576Cr

4682-34.2 (-0.73%)

4590

4738

1,77,251Cr

1134.4-18.6 (-1.61%)

1105.40

1166.90

1,11,232Cr

2069.2+16.4 (0.80%)

1988.90

2069.20

1,09,797Cr

1311.3-15.9 (-1.20%)

1292

1334.20

1,05,290Cr

1229.4+25.6 (2.13%)

1167.20

1235

99,753Cr

2400-100 (-4.00%)

2342

2510.90

97,850Cr

1706.9+24.9 (1.48%)

1633

1715

97,015Cr

1935-77.9 (-3.87%)

1933.20

2020.90

89,629Cr

Mankind Pharma Share Price

2400.00+31.50 (+1.33%)

-2.44% past 1 Year

Open a free Demat account in minutes to start investing and screening .

Mankind Pharma Share Price

2400.00+31.50 (+1.33%)

-2.44% past 1 Year

Financial overview

Compounded Sales Growth

10 years14%

5 years18%

3 years18%

Last year17%

Compounded Profit Growth

10 years13%

5 years9%

3 years14%

Last year-3%

Stock Price CAGR

10 years-

5 years-

3 years10%

1 year-4%

Return on Equity

10 years23%

5 years20%

3 years18%

Last year13%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
14%	18%	18%	17%
13%	9%	14%	-3%
-	-	10%	-4%
23%	20%	18%	13%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

ZYDUSLIFE

LAURUSLABS

CIPLA

DRREDDY

MANKIND

AUROPHARMA

LUPIN

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,760	₹421539 Cr	34.85	12.07	62.82	₹11479 Cr
9,426	₹247576 Cr	84.64	34.04	128.41	₹2568 Cr
4,682	₹177251 Cr	81.27	16.72	97.06	₹2163 Cr
1,134.4	₹111232 Cr	24.65	9.42	62.53	₹5040 Cr
2,069.2	₹109797 Cr	100.42	6.8	29.25	₹889 Cr
1,311.3	₹105290 Cr	31.24	9.77	57.87	₹3879 Cr
1,229.4	₹99753 Cr	30.96	5.32	63.99	₹4196 Cr
2,400	₹97850 Cr	47.9	13.75	71.08	₹1913 Cr
1,706.9	₹97015 Cr	26.13	17.95	96.84	₹3505 Cr
1,935	₹89629 Cr	16.21	30.95	154.35	₹5333 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Name

Net Revenue

Other Income

Total Revenue

Total Expenditure

Operating Profit

Interest Expense

PBT

Net Profit

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
₹4031 Cr	₹3443 Cr	₹3567 Cr	₹3697 Cr	₹3570 Cr	₹3079 Cr	₹3199 Cr	₹3061 Cr	₹2868 Cr	₹2422 Cr	₹2607 Cr	₹2708 Cr	₹2579 Cr	₹2053 Cr	₹2091 Cr	₹2426 Cr	₹2180 Cr	₹1726 Cr
₹45 Cr	₹114 Cr	₹73 Cr	₹92 Cr	₹80 Cr	₹251 Cr	₹77 Cr	₹109 Cr	₹99 Cr	₹92 Cr	₹70 Cr	₹60 Cr	₹59 Cr	₹48 Cr	₹37 Cr	₹27 Cr	₹17 Cr	₹34 Cr
₹4076 Cr	₹3557 Cr	₹3640 Cr	₹3789 Cr	₹3650 Cr	₹3331 Cr	₹3276 Cr	₹3170 Cr	₹2967 Cr	₹2514 Cr	₹2677 Cr	₹2768 Cr	₹2637 Cr	₹2100 Cr	₹2128 Cr	₹2453 Cr	₹2197 Cr	₹1759 Cr
₹3200 Cr	₹2736 Cr	₹2870 Cr	₹2998 Cr	₹2942 Cr	₹2627 Cr	₹2570 Cr	₹2315 Cr	₹2299 Cr	₹1936 Cr	₹2110 Cr	₹2122 Cr	₹2011 Cr	₹1721 Cr	₹1739 Cr	₹1914 Cr	₹1802 Cr	₹1488 Cr
₹1101 Cr	₹1044 Cr	₹992 Cr	₹1013 Cr	₹927 Cr	₹935 Cr	₹893 Cr	₹956 Cr	₹771 Cr	₹678 Cr	₹677 Cr	₹743 Cr	₹713 Cr	₹464 Cr	₹474 Cr	₹618 Cr	₹473 Cr	₹318 Cr
₹110 Cr	₹142 Cr	₹157 Cr	₹170 Cr	₹171 Cr	₹191 Cr	₹221 Cr	₹7 Cr	₹11 Cr	₹9 Cr	₹9 Cr	₹9 Cr	₹6 Cr	₹5 Cr	₹13 Cr	₹10 Cr	₹16 Cr	₹13 Cr
₹766 Cr	₹656 Cr	₹506 Cr	₹622 Cr	₹537 Cr	₹513 Cr	₹485 Cr	₹849 Cr	₹657 Cr	₹570 Cr	₹558 Cr	₹638 Cr	₹620 Cr	₹375 Cr	₹377 Cr	₹529 Cr	₹378 Cr	₹258 Cr
₹570 Cr	₹556 Cr	₹411 Cr	₹518 Cr	₹441 Cr	₹422 Cr	₹381 Cr	₹656 Cr	₹539 Cr	₹474 Cr	₹455 Cr	₹508 Cr	₹489 Cr	₹291 Cr	₹293 Cr	₹419 Cr	₹294 Cr	₹188 Cr

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Minority Interest

Secured Loans

Unsecured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Less Impairment of Assets

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015
—	—	—	—	—	—	—	—	—	—	—	—
₹41 Cr	₹41 Cr	₹40 Cr	₹40 Cr	₹40 Cr	₹40 Cr	₹40 Cr	₹40 Cr	₹40 Cr	₹20 Cr	₹20 Cr	₹20 Cr
₹48 Cr	₹44 Cr	₹23 Cr	₹6 L	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹16211 Cr	₹14248 Cr	₹9300 Cr	₹7395 Cr	₹6115 Cr	₹4682 Cr	₹3445 Cr	₹2783 Cr	₹2841 Cr	₹2907 Cr	₹2237 Cr	₹2035 Cr
₹16211 Cr	₹14248 Cr	₹9300 Cr	₹7395 Cr	₹6115 Cr	₹4682 Cr	₹3445 Cr	₹2783 Cr	₹2841 Cr	₹2907 Cr	₹2237 Cr	₹2035 Cr
₹16300 Cr	₹14332 Cr	₹9363 Cr	₹7435 Cr	₹6155 Cr	₹4722 Cr	₹3485 Cr	₹2823 Cr	₹2881 Cr	₹2927 Cr	₹2257 Cr	₹2055 Cr
₹261 Cr	₹236 Cr	₹213 Cr	₹188 Cr	₹161 Cr	₹141 Cr	₹186 Cr	₹159 Cr	₹134 Cr	₹98 Cr	₹29 Cr	₹16 Cr
₹2483 Cr	₹5078 Cr	₹25 Cr	₹23 Cr	₹49 Cr	₹57 Cr	₹58 Cr	₹25 Cr	₹3 Cr	₹1 Cr	₹10 L	₹2 L
₹339 Cr	₹448 Cr	₹0	₹0	₹25 L	₹25 L	₹0	₹0	₹34 L	₹1 Cr	₹2 Cr	₹0
₹1515 Cr	₹1705 Cr	₹9 Cr	₹48 Cr	₹16 Cr	-₹36 Cr	-₹40 Cr	-₹7 Cr	₹2 Cr	₹20 Cr	₹14 Cr	-₹72 L
₹101 Cr	₹34 Cr	₹31 Cr	₹31 Cr	₹23 Cr	₹13 Cr	₹22 Cr	₹14 Cr	₹8 Cr	₹6 Cr	₹47 L	₹16 Cr
₹249 Cr	₹155 Cr	₹123 Cr	₹98 Cr	₹80 Cr	₹72 Cr	₹63 Cr	₹45 Cr	₹36 Cr	₹25 Cr	₹18 Cr	₹13 Cr
₹4687 Cr	₹7420 Cr	₹187 Cr	₹199 Cr	₹169 Cr	₹107 Cr	₹103 Cr	₹78 Cr	₹49 Cr	₹53 Cr	₹34 Cr	₹28 Cr
—	—	—	—	—	—	—	—	—	—	—	—
₹1341 Cr	₹1133 Cr	₹777 Cr	₹1008 Cr	₹1076 Cr	₹667 Cr	₹745 Cr	₹562 Cr	₹649 Cr	₹492 Cr	₹419 Cr	₹380 Cr
₹3702 Cr	₹1335 Cr	₹756 Cr	₹386 Cr	₹473 Cr	₹283 Cr	₹180 Cr	₹117 Cr	₹162 Cr	₹140 Cr	₹101 Cr	₹52 Cr
₹639 Cr	₹2513 Cr	₹151 Cr	₹115 Cr	₹795 Cr	₹158 Cr	₹44 Cr	₹241 Cr	₹404 Cr	₹10 Cr	₹0	₹0
₹825 Cr	₹682 Cr	₹436 Cr	₹354 Cr	₹280 Cr	₹245 Cr	₹281 Cr	₹104 Cr	₹81 Cr	₹21 Cr	₹8 Cr	₹1 Cr
₹6507 Cr	₹5664 Cr	₹2120 Cr	₹1863 Cr	₹2623 Cr	₹1353 Cr	₹1251 Cr	₹1024 Cr	₹1296 Cr	₹663 Cr	₹528 Cr	₹433 Cr
₹27755 Cr	₹27652 Cr	₹11883 Cr	₹9686 Cr	₹9108 Cr	₹6324 Cr	₹5025 Cr	₹4084 Cr	₹4360 Cr	₹3741 Cr	₹2848 Cr	₹2532 Cr
₹925 Cr	₹1019 Cr	₹89 Cr	₹48 Cr	₹83 Cr	₹35 Cr	₹242 Cr	₹361 Cr	₹16 Cr	₹31 Cr	₹21 Cr	₹24 Cr
₹6022 Cr	₹8300 Cr	₹196 Cr	₹163 Cr	₹868 Cr	₹235 Cr	₹128 Cr	₹270 Cr	₹407 Cr	₹13 Cr	₹2 Cr	₹2 L
—	—	—	—	—	—	—	—	—	—	—	—
₹21377 Cr	₹20917 Cr	₹5910 Cr	₹5233 Cr	₹4247 Cr	₹2160 Cr	₹1988 Cr	₹1681 Cr	₹1230 Cr	₹915 Cr	₹489 Cr	₹403 Cr
₹2756 Cr	₹1912 Cr	₹1370 Cr	₹988 Cr	₹664 Cr	₹501 Cr	₹373 Cr	₹282 Cr	₹216 Cr	₹122 Cr	₹42 Cr	₹126 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹21 Cr	₹0	₹0	₹0	₹0	₹0
₹18620 Cr	₹19005 Cr	₹4540 Cr	₹4245 Cr	₹3583 Cr	₹1659 Cr	₹1594 Cr	₹1399 Cr	₹1014 Cr	₹793 Cr	₹447 Cr	₹277 Cr
₹655 Cr	₹306 Cr	₹207 Cr	₹493 Cr	₹670 Cr	₹372 Cr	₹313 Cr	₹327 Cr	₹482 Cr	₹302 Cr	₹139 Cr	₹44 Cr
₹448 Cr	₹351 Cr	₹310 Cr	₹271 Cr	₹235 Cr	₹206 Cr	₹164 Cr	₹216 Cr	₹139 Cr	₹101 Cr	₹54 Cr	₹42 Cr
₹448 Cr	₹351 Cr	₹310 Cr	₹271 Cr	₹235 Cr	₹206 Cr	₹164 Cr	₹216 Cr	₹139 Cr	₹101 Cr	₹54 Cr	₹42 Cr
₹555 Cr	₹293 Cr	₹164 Cr	₹188 Cr	₹164 Cr	₹158 Cr	₹106 Cr	₹118 Cr	₹77 Cr	₹260 Cr	₹336 Cr	₹270 Cr
₹50 Cr	₹189 Cr	₹14 Cr	₹99 Cr	₹13 Cr	₹17 Cr	₹16 Cr	₹14 Cr	₹9 Cr	₹9 Cr	₹7 Cr	₹42 Cr
₹20801 Cr	₹20663 Cr	₹5315 Cr	₹5358 Cr	₹4702 Cr	₹2417 Cr	₹2203 Cr	₹2085 Cr	₹1787 Cr	₹1672 Cr	₹1142 Cr	₹859 Cr
—	—	—	—	—	—	—	—	—	—	—	—
₹1537 Cr	₹1691 Cr	₹2258 Cr	₹1075 Cr	₹874 Cr	₹1306 Cr	₹665 Cr	₹543 Cr	₹650 Cr	₹848 Cr	₹655 Cr	₹737 Cr
₹2144 Cr	₹2094 Cr	₹1553 Cr	₹1498 Cr	₹1760 Cr	₹1184 Cr	₹899 Cr	₹821 Cr	₹789 Cr	₹789 Cr	₹619 Cr	₹596 Cr
₹1730 Cr	₹1538 Cr	₹848 Cr	₹576 Cr	₹388 Cr	₹331 Cr	₹531 Cr	₹220 Cr	₹297 Cr	₹166 Cr	₹193 Cr	₹197 Cr
₹483 Cr	₹555 Cr	₹708 Cr	₹453 Cr	₹406 Cr	₹701 Cr	₹420 Cr	₹141 Cr	₹139 Cr	₹146 Cr	₹90 Cr	₹39 Cr
₹101 Cr	₹97 Cr	₹104 Cr	₹64 Cr	₹171 Cr	₹83 Cr	₹10 Cr	₹8 Cr	₹469 Cr	₹31 Cr	₹86 Cr	₹62 Cr
₹957 Cr	₹1011 Cr	₹1093 Cr	₹657 Cr	₹804 Cr	₹276 Cr	₹294 Cr	₹209 Cr	₹230 Cr	₹89 Cr	₹64 Cr	₹42 Cr
₹6952 Cr	₹6986 Cr	₹6566 Cr	₹4325 Cr	₹4404 Cr	₹3880 Cr	₹2820 Cr	₹1943 Cr	₹2574 Cr	₹2069 Cr	₹1707 Cr	₹1673 Cr
₹444 Cr	₹1322 Cr	₹4446 Cr	₹2461 Cr	₹1780 Cr	₹2526 Cr	₹1569 Cr	₹919 Cr	₹1277 Cr	₹1406 Cr	₹1179 Cr	₹1240 Cr
₹27755 Cr	₹27652 Cr	₹11883 Cr	₹9686 Cr	₹9108 Cr	₹6324 Cr	₹5025 Cr	₹4084 Cr	₹4360 Cr	₹3741 Cr	₹2848 Cr	₹2532 Cr
₹394	₹346	₹233	₹186	₹154	₹118	₹87	₹70	₹72	₹1,461	₹1,127	₹1,026
₹394	₹346	₹233	₹186	₹154	₹118	₹87	₹70	₹72	₹73	₹56	₹51

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Cash & Cash Equivalent of Subsidiaries under liquidations

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015
₹2333 Cr	₹2525 Cr	₹2399 Cr	₹1671 Cr	₹1975 Cr	₹1692 Cr	₹1438 Cr	₹865 Cr	₹995 Cr	₹906 Cr	₹784 Cr	₹621 Cr
₹1277 Cr	₹602 Cr	₹212 Cr	₹298 Cr	₹31 Cr	-₹6 Cr	₹105 Cr	₹87 Cr	₹109 Cr	₹20 Cr	-₹19 Cr	₹13 Cr
₹105 Cr	-₹146 Cr	-₹18 Cr	₹167 Cr	-₹586 Cr	-₹95 Cr	-₹140 Cr	-₹10 Cr	-₹141 Cr	-₹12 Cr	₹17 Cr	-₹121 Cr
₹3714 Cr	₹2980 Cr	₹2594 Cr	₹2136 Cr	₹1419 Cr	₹1591 Cr	₹1403 Cr	₹942 Cr	₹963 Cr	₹914 Cr	₹782 Cr	₹512 Cr
₹3121 Cr	₹2413 Cr	₹2152 Cr	₹1813 Cr	₹920 Cr	₹1137 Cr	₹1072 Cr	₹600 Cr	₹639 Cr	₹628 Cr	₹537 Cr	₹280 Cr
-₹196 Cr	-₹12683 Cr	-₹2082 Cr	-₹1054 Cr	-₹1369 Cr	-₹1222 Cr	-₹439 Cr	-₹444 Cr	-₹505 Cr	-₹625 Cr	-₹152 Cr	-₹348 Cr
-₹2953 Cr	₹10233 Cr	₹5 Cr	-₹740 Cr	₹605 Cr	-₹8 Cr	-₹527 Cr	-₹175 Cr	-₹89 Cr	₹2 Cr	-₹361 Cr	₹9 Cr
-₹28 Cr	-₹37 Cr	₹76 Cr	₹19 Cr	₹155 Cr	-₹93 Cr	₹106 Cr	-₹19 Cr	₹46 Cr	₹5 Cr	₹25 Cr	-₹59 Cr
₹404 Cr	₹382 Cr	₹305 Cr	₹283 Cr	₹127 Cr	₹220 Cr	₹116 Cr	₹136 Cr	₹89 Cr	₹82 Cr	₹53 Cr	₹98 Cr
₹0	-₹9 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹0	₹67 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹16 Cr	₹1 Cr	₹1 Cr	₹2 Cr	₹48 L	₹38 L	₹4 Cr	-₹2 L	₹3 L	-₹6 L	-₹4 L	₹0
₹392 Cr	₹404 Cr	₹382 Cr	₹305 Cr	₹283 Cr	₹127 Cr	₹226 Cr	₹116 Cr	₹135 Cr	₹87 Cr	₹78 Cr	₹39 Cr

Fundamental Ratios

Consolidated

Standalone

No results found

Mankind Pharma Share Price

2400.00+31.50 (+1.33%)

-2.44% past 1 Year

Shareholding summary

Promoters

72.63%

FII

9.45%

DII

4.48%

10.87%

Others

2.57%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
72.63%	72.66%	72.66%	72.67%	72.68%	72.70%
9.45%	10.24%	11.34%	12.83%	13.07%	12.92%
4.48%	4.06%	3.92%	4.09%	4.12%	3.77%
10.87%	10.36%	9.30%	7.78%	7.34%	7.67%
2.57%	2.68%	2.78%	2.63%	2.79%	2.94%

Bulk & block deals

Name

Goldman Sachs Bank Europe Se - Odi

Goldman Sachs (Singapore) Pte - Odi

Goldman Sachs Bank Europe Se - Odi

Goldman Sachs (Singapore) Pte - Odi

Goldman Sachs (Singapore) Pte.- Odi

Copthall Mauritius Investment Limited

Orbimed Genesis Master Fund L.p.

Copthall Mauritius Investment Limited

Icici Prudential Mutual Fund A/C Icici Prudential India Opportunities Fund

Icici Prudential Mutual Fund

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
14 Oct 2025	Purchase	13.37 Cr	₹2,430	55 K	Block	0.013316	NSE
14 Oct 2025	Sell	13.37 Cr	₹2,430	55 K	Block	0.013316	NSE
13 Oct 2025	Purchase	10.31 Cr	₹2,440	42.24 K	Block	0.010228	NSE
13 Oct 2025	Sell	10.31 Cr	₹2,440	42.24 K	Block	0.010228	NSE
09 May 2025	Purchase	13.39 Cr	₹2,434.10	55 K	Block	0.013316	BSE
09 May 2025	Sell	13.39 Cr	₹2,434.10	55 K	Block	0.013316	BSE
05 Feb 2025	Purchase	11.50 Cr	₹2,555.10	45 K	Block	0.010895	NSE
05 Feb 2025	Sell	11.50 Cr	₹2,555.10	45 K	Block	0.010895	NSE
10 Jul 2024	Purchase	91.03 Cr	₹2,082	4.37 L	Block	0.105857	NSE
10 Jul 2024	Purchase	75.44 Cr	₹2,082	3.62 L	Block	0.087722	NSE

Insider trading & SAST

Client name

Arjun Juneja

Puja Juneja

Sheetal Arora

Beige Ltd & Link Investment Trust

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
09 Feb 2024	Promoter Group	Disposal	0.5994	2.04	506 Cr	₹2,107.35	24.01 L	08 Feb 2024	Block Deal	81,54,463	Insider Trading	—	Equity Shares
09 Feb 2024	Promoter Group	Disposal	0.567	2.88	478.65 Cr	₹2,107.35	22.71 L	08 Feb 2024	Block Deal	1,15,33,906	Insider Trading	—	Equity Shares
09 Feb 2024	Promoter	Disposal	0.4536	4.81	382.92 Cr	₹2,107.35	18.17 L	08 Feb 2024	Block Deal	1,92,77,647	Insider Trading	—	Equity Shares
04 Jan 2024	Other	Disposal	4.49	3.01	0	—	1.80 Cr	12 Dec 2023	Market	1,20,44,132	SAST	29(2)	—

Mankind Pharma Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Mankind Pharma Share Price

Mankind Pharma Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Mankind Pharma Share Price

Mankind Pharma Share Price

Oscillators

Moving averages

Mankind Pharma Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Mankind Pharma Share Price

Corporate Actions

Company details

Mankind Pharma Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Mankind Pharma Share Price

News

Kotak upgrades Mankind Pharma to Buy, sets Rs 3,000 target price

Mankind Pharma sees Rs 28.49 crores NSE block trade at premium pricing

Mankind Pharma receives strong ESG leader rating of 68.21 for FY26

Mankind Pharma sees Rs 41.05 crores NSE block trade at Rs 2254.60

Mankind Pharma subsidiary gets approval for voluntary liquidation process

Mankind Pharma exits non-core hospitality arm via Rs 49 crore stake sale

Mankind Pharma board approves voluntary liquidation of key subsidiary BSVL

Mankind Pharma gets CRISIL ESG rating upgraded to Strong category

Mankind Pharma signs exclusive insulin degludec and combo licensing deal in India

Mankind Pharma sees Rs 24.26 crores NSE block trade at Rs 2400.40

Mankind Pharma sees Rs 24.12 crores NSE block trade at premium price

Mankind Pharma sees Rs 52.14 crore NSE block trade in 216,181 shares

Mankind Pharma sees Rs 25.89 crores NSE block trade at Rs 2484.90

Mankind Pharma reports strong Q1 revenue growth on year-over-year basis

Mankind Pharma Q1 EBITDA jumps year on year with stronger margins

Mankind Pharma Q1 consolidated net profit rises sharply on strong YoY growth

Mankind Pharma records Rs 18.34 crores NSE block trade for 71,310 shares

Mankind Pharma records NSE block trade worth Rs 19.57 crores

Mankind Pharma sees Rs 25.51 crores NSE block deal at premium price

Mankind Pharma to hold Q1 earnings call on July 30

Mankind Pharma Ltd Share Price Today

Mankind Pharma Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator